Marc Rosenbaum, who already knows the accounting ropes at NuVasive, Inc. has been promoted to Corporate Controller.
Marc Rosenbaum Promoted to Corporate Controller at NuVasive
1 min read Premium comments
#nuvasiveSecondary#marcrosembaum
According to the company, “Rosenbaum has been with NuVasive for more than four years and expands his senior accounting duties to now include serving as the corporate controller for the Company.”
“He began his accounting career at Deloitte and has held a variety of senior accounting roles at Dura Pharmaceuticals, Elan Pharmaceuticals, Gen-Probe and Hologic overseeing both internal and external financial reporting.”
“He graduated with a Bachelor of Arts in Business Economics from the University of California, Santa Barbara.”
Raj Asarpota, executive vice president and chief financial officer of NuVasive, told OTW, “Together, the appointments of Pecora, Ribar and Rosenbaum reflect our commitment to building a world-class finance leadership team at NuVasive. These three professionals bring extensive finance expertise gained from years in the medical device arena that will allow NuVasive to continue to grow strategically as we ramp up operations in West Carrolton and continue to expand our footprint in global markets.”
React:
Discussion
This is a fascinating development. In my practice we've seen similar outcomes with the revised protocol. The key differentiator seems to be patient selection criteria. Has anyone else noticed the correlation with BMI thresholds?
Great point. I'd push back slightly on the conclusion, the sample size in the cited study is too small to draw population-level inferences. That said, the directional signal is compelling and worth a larger RCT.
We implemented a similar approach last year. Early results are promising but we're still gathering 12-month follow-up data. Happy to share our protocol if anyone is interested.
Join the conversation
Orthopedic professionals are discussing this. Sign in and upgrade to read every comment and add your voice.